Evidence strength for the context described on this page.
PEPTIDE ATLAS / SKIN & HAIR / GHK-CU
GHK-Cu

A copper-binding cosmetic peptide with a very different risk profile when injected.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What GHK-Cu is.
A naturally occurring copper-binding tripeptide used in topical cosmetic products. Topical cosmetic use, compounded injection and research-grade powder should be treated as distinct categories.
In laboratory models it influences extracellular matrix, wound signaling and gene expression. Human cosmetic outcomes are less certain than mechanistic marketing suggests.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- May support appearance-focused skin formulations
- Limited human evidence for hair or wound outcomes
- Systemic rejuvenation
- Safe injectable anti-aging
- Clinically meaningful hair regrowth
- That copper delivery is universally beneficial
Evidence grade: Early human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Formulation and intended use matter. An oral or topical consumer product does not establish the safety of an injectable preparation.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Irritation, discoloration or dermatitis
- Photography under consistent lighting for cosmetic claims
SAFETY
Risks, red flags and reasons to avoid it.
- Topical irritation or allergy
- Injectable aggregation, immunogenicity and impurities
- Limited human safety data for systemic use
- Injection
- Broken or infected skin unless a clinician directs care
- Assuming cosmetic-ingredient status means injectable safety
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
Choose a tested finished product.
Widely available in cosmetics; injectable use is not FDA-approved.
Route matters. A topical ingredient with modest cosmetic evidence does not become a proven systemic longevity therapy when placed in a vial.
Compare quality-first products
Coming soon: identity testing, contaminant screening, transparent sourcing and dose-per-serving comparisons.
Get the product shortlist →NEXT STEP